<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lisdexamfetamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lisdexamfetamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lisdexamfetamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12052" href="/d/html/12052.html" rel="external">see "Lisdexamfetamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13015" href="/d/html/13015.html" rel="external">see "Lisdexamfetamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58227438"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">ADHD Stimulant Safety Alert</span>
<span class="collapsible-date">May 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA is requiring updates to the Boxed Warning and other sections in the prescribing information of prescription stimulants to ensure consistency across the class of medicines and address continuing concerns of misuse, abuse, addiction, and overdose. The current prescribing information for some prescription stimulants does not provide up-to-date warnings about the harms of misuse and abuse, and particularly that most individuals who misuse prescription stimulants get them from other family members or peers. The FDA is adding information that patients should never share prescription stimulants with anyone, and the Boxed Warning will describe the risks of misuse, abuse, addiction, and overdose consistently across all medicines in the class, as well as advise health care professionals to monitor patients closely for signs and symptoms of misuse, abuse, and addiction. Information on these risks is being required in several sections of the prescribing information, including Warnings and Precautions, Drug Abuse and Dependence, Overdosage, and Patient Counseling sections; updates to existing Medication Guides are also required to help educate patients and caregivers about these risks.</p>
<p style="text-indent:0em;">Further information can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions&amp;token=2htBI%2BZJP9KguLNT5e%2FO5JB3a3lhB47gC48SVmgo9Z800H4ddHXFGN3vhQ%2BWdW5yurFpw9BeJ%2FM6gAUY1Tt1jyGUCu7UWgLKdtpLZMlcF4ajBtdi8HzFE4w2iTIacoZKOst31pB5%2B5utMl%2FdfB4GdprCpFXm3czU9pi4wB1ZjvM%3D&amp;TOPIC_ID=10143" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709015"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lisdexamfetamine has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Before prescribing lisdexamfetamine, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout lisdexamfetamine treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520558"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vyvanse</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868856"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vyvanse</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4425750"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Nervous System Stimulant</li></ul></div>
<div class="block doa drugH1Div" id="F6126904"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Prior to treatment, assess for presence of cardiac disease and assess for risk of abuse.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b>
<b>Oral:</b> Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg at weekly intervals until optimal response is obtained; maximum: 70 mg/day. <b>Note:</b> Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder:</b>
<b>Oral:</b> Initial: 30 mg once daily in the morning; may titrate in increments of 20 mg at weekly intervals to target dose of 50 to 70 mg once daily (maximum: 70 mg/day); discontinue use if binge eating does not improve.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991377"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 50 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 30 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD requiring hemodialysis: Maximum dose: 30 mg/day; lisdexamfetamine and dextroamphetamine are not dialyzable.</p></div>
<div class="block doha drugH1Div" id="F50988515"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F49115760"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; initiate dose at the low end of the dosing range.</p></div>
<div class="block dop drugH1Div" id="F4425789"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13015" href="/d/html/13015.html" rel="external">see "Lisdexamfetamine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b> Children ≥6 years and Adolescents: Capsules, chewable tablets: Oral: Initial: 20 to 30 mg once daily in the morning; may increase in increments of 10 mg/day or 20 mg/day at 3- to 7-day intervals until optimal response is obtained; use lowest effective individualized dose; maximum daily dose: 70 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22003063','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22003063','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128467"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: Capsules, chewable tablets: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Maximum daily dose: 50 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Maximum daily dose: 30 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD requiring hemodialysis: Maximum daily dose: 30 mg/day; lisdexamfetamine and dextroamphetamine are not dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F51128468"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56393058"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular events including myocardial infarctions (MI), stroke, sudden cardiac death (SCD),<b> increased heart rate</b>, and <b>increased blood pressure</b> have been reported with the use of CNS stimulants in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20141706','lexi-content-ref-17577466','lexi-content-ref-28667569','lexi-content-ref-16182674','lexi-content-ref-16549404','lexi-content-ref-22318795','lexi-content-ref-32792083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20141706','lexi-content-ref-17577466','lexi-content-ref-28667569','lexi-content-ref-16182674','lexi-content-ref-16549404','lexi-content-ref-22318795','lexi-content-ref-32792083'])">Ref</a></span>); <b>syncope</b> and severe <b>cardiac arrythmia</b> have been described with lisdexamfetamine use in children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28667569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28667569'])">Ref</a></span>). CNS stimulants have also been associated with SCD in children and adolescents with preexisting structural cardiac abnormalities. Available data in patients without congenital heart disease are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-23382829','lexi-content-ref-27245699','lexi-content-ref-22682429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-23382829','lexi-content-ref-27245699','lexi-content-ref-22682429'])">Ref</a></span>). A large retrospective cohort study showed an overall low incidence and risk of serious cardiovascular events in children and young adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22043968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22043968'])">Ref</a></span>); similarly, retrospective claims databases have not shown an increase in serious cardiovascular events (MI, sudden death, stroke) with stimulant use in young and middle-aged adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22161946','lexi-content-ref-23382829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22161946','lexi-content-ref-23382829'])">Ref</a></span>). A study evaluating the cardiac effects of long-term treatment with lisdexamfetamine in adults did not find any clinically significant changes in cardiac structure or function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22559155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22559155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Dose-related; amphetamines increase the mean heart rate and systolic blood pressure by mediating noradrenergic and dopaminergic transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31133823','lexi-content-ref-20693523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31133823','lexi-content-ref-20693523'])">Ref</a></span>). This increase in heart rate and blood pressure can ultimately lead to cardiovascular events such as arrhythmias and/or MI.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; MI and SCD usually occur within hours (especially in cases of overdose), but arrhythmias usually occur with long term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26998366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26998366'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior structural cardiac abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20693523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20693523'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of SCD or other cardiovascular diseases (eg, MI, cardiac arrhythmias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of QTc-prolonging medications may increase the risk of arrhythmias</p>
<p style="text-indent:-2em;margin-left:6em;">• Strenuous exercise and dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Growth suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth retardation</b>, including <b>weight loss</b> and decreased rate of growth, has been reported in pediatric patients. Statistically significant decreases in weight, height, and BMI in children and adolescents (age range: 6 to 13 years) have been observed in short- and long-term studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17577466','lexi-content-ref-24788672','lexi-content-ref-28667569','lexi-content-ref-20215923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17577466','lexi-content-ref-24788672','lexi-content-ref-28667569','lexi-content-ref-20215923'])">Ref</a></span>). Similarly, statistically significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed in pediatric patients (age range: 8 to 17 years) actively treated with stimulants (including, but not limited to lisdexamfetamine) when compared to matched unmedicated controls; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched controls (38.3% vs 21.6%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26398435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26398435'])">Ref</a></span>). The effect of lisdexamfetamine on weight in adults is variable and the long-term effects of treatment on growth into adulthood have yet to be determined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; possibly due to effects on CNS growth factors and hepatic growth factors and direct cartilage effects. Weight loss may result from appetite suppression, reduced food intake, increased activity, and metabolic shifts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18580502','lexi-content-ref-7580171','lexi-content-ref-9685453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18580502','lexi-content-ref-7580171','lexi-content-ref-9685453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Growth suppression in children: Varied; appears to occur within 4 weeks of initiating treatment (median 29 days; range: 1 to 677 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672','lexi-content-ref-28667569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672','lexi-content-ref-28667569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18622366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18622366'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment/cumulative exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672','lexi-content-ref-20215923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672','lexi-content-ref-20215923'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline height and/or weight above CDC norms upon initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672','lexi-content-ref-20215923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672','lexi-content-ref-20215923'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• No prior history of stimulant use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24788672','lexi-content-ref-20215923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24788672','lexi-content-ref-20215923'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset psychosis or <b>mania</b> and exacerbation of psychotic or manic symptoms (eg, delusional thinking, hallucination) may occur with neurostimulant use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28667569','lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28667569','lexi-content-ref-26485338'])">Ref</a></span>). <b>Aggressive behavior</b>, <b>hostility</b>, and <b>suicidal ideation</b> have also been reported with lisdexamfetamine use in children and adolescents, however a causal relationship has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28667569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28667569'])">Ref</a></span>). A study of commercial insurance claims data from 221,846 patients (age: 13 to 25 years) prescribed amphetamines or methylphenidate reported a higher risk of psychosis with amphetamine products compared to methylphenidate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>). Studies in adults have suggested that the resolution of an amphetamine-associated psychotic episode may be incomplete without treatment and may take up to 6 months even if abstinence occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31681046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31681046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Psychosis: Amphetamine stimulates the release of dopamine from presynaptic nerve endings and prevents its reuptake. This leads to an increased concentration of dopamine in the neuronal synapse, leading to glutamate dysregulation. Increased dopamine and glutamate dysregulation have been associated with the development of psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31681046','lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31681046','lexi-content-ref-30893533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed and varied; a study of commercial insurance claims data from 221,846 patients (age: 13 to 25 years) prescribed amphetamines or methylphenidate reported a mean time of 128 days (IQR: 48 to 333 days) from the time medication was dispensed to the first psychotic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>). In cases of overdose/intoxication the onset of symptoms is usually acute and within hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting mood or psychotic disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of substance use/abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of mood and psychotic disorders (eg, major depression, bipolar disorder, and schizophrenia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26719291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26719291'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (children, adolescents, and young adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome may occur when amphetamines are used in combination with drugs that affect the serotonergic neurotransmitter system in all ages. Early symptoms of serotonin syndrome include tachycardia, shivering, diarrhea, diaphoresis, muscle cramps, agitation, and increased body temperature; these symptoms are usually followed by hypertension, hyperthermia, hyperreflexia, delirium, tremors, and rigidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23343808','lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23343808','lexi-content-ref-25653508'])">Ref</a></span>). Prompt treatment is needed to minimize risk of adverse outcome including death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23343808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23343808'])">Ref</a></span>). The incidence of serotonin syndrome from stimulants use is unknown, likely due to under reporting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Amphetamines increase serotonin release and inhibit reuptake, which can lead to dangerously high extracellular concentration of serotonin especially when used in combination with other drugs that also increase serotonin concentrations (eg, CYP2D6 inhibitors, serotonin reuptake inhibitors, serotonin-norepinephrine uptake inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31523132','lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31523132','lexi-content-ref-25653508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; symptoms usually begin within 24 hours of ingestion of the causative agent(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31523132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31523132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphism: Poor CYP2D6 metabolizers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of CYP2D6 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>); consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>); consult drug interactions database for more information.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F4425761"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (children and adolescents: 34% to 39%; adults 8% to 27%), upper abdominal pain (children: 12%; adults: 2%), xerostomia (children and adolescents: 4% to 5%; adults: 26% to 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (13% to 27%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (adults: 3%)<span class="lexi-table-link-container"> (<a aria-label="Increased Blood Pressure table link" class="lexi-table-link" data-table-id="lexi-content-increased-blood-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-blood-pressure')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Blood Pressure</span>, increased heart rate (adults: 2% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Increased Heart Rate table link" class="lexi-table-link" data-table-id="lexi-content-increased-heart-rate" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-heart-rate')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Heart Rate</span>, palpitations (adolescents and adults: 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Blood Pressure" frame="border" id="lexi-content-increased-blood-pressure" rules="all">
<caption style="text-align:center;">
<b>Lisdexamfetamine: Adverse Reaction: Increased Blood Pressure</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lisdexamfetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lisdexamfetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">358</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">62</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Heart Rate" frame="border" id="lexi-content-increased-heart-rate" rules="all">
<caption style="text-align:center;">
<b>Lisdexamfetamine: Adverse Reaction: Increased Heart Rate</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lisdexamfetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lisdexamfetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">358</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">62</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Binge eating disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">373</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">372</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (adults: 3% to 4%), pruritus (adults: 2%), skin rash (children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (adults: 1%), weight loss (children and adolescents: 9%; adults: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (2% to 5%), constipation (adults: 6%), diarrhea (adults: 4% to 7%), gastroenteritis (adults: 2%), nausea (6% to 7%), vomiting (children: 9%; adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (adults: 3%), urinary tract infection (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (adults: 3%), anxiety (adults: 5% to 6%), dizziness (children: 5%), drowsiness (children: 2%), emotional lability (children: 3%), increased energy (adults: 2%), irritability (children: 10%), jitteriness (adults: 4% to 6%), nightmares (adults: 2%), paresthesia (adults: 2%), restlessness (adults: 2% to 3%), tic disorder (children: 2%), tremor (adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (adults: 2%), oropharyngeal pain (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Drug abuse, drug dependence, talkativeness</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (Coghill 2017), cardiomyopathy, chest pain, peripheral vascular insufficiency, Raynaud disease (Gnanavel 2018), syncope (Coghill 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Brahm 2009), dermatillomania, Stevens-Johnson syndrome, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, growth retardation (Coghill 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism, dysgeusia, mesenteric ischemia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Frequent erections (Majeed 2017), priapism (Majeed 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (eosinophilic) (Hood 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Coghill 2017), depression (Coghill 2017, Pozzi 2019), euphoria (Pozzi 2019), headache (Coghill 2017), hostility (Coghill 2017), mania (Coghill 2017), outbursts of anger (Coghill 2017), paranoid ideation (including obsessive thoughts) (Pozzi 2019), psychomotor agitation (Coghill 2014), seizure, suicidal ideation (Coghill 2017), tic disorder (including motor tics and vocal tics)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, angle-closure glaucoma (acute, bilateral) (Davanian 2021), blurred vision, diplopia, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying (Pozzi 2019)</p></div>
<div class="block coi drugH1Div" id="F4425757"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amphetamine products or any component of the formulation; concurrent use of monoamine oxidase (MAO) inhibitor (including linezolid or IV methylene blue), or within 14 days of the last MAO inhibitor dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Known hypersensitivity or idiosyncrasy to sympathomimetic amines; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse</p></div>
<div class="block war drugH1Div" id="F4425758"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Peripheral vasculopathy effects have been observed at different times, at therapeutic doses, and in all age groups. Digital ulceration and/or soft tissue breakdown have been observed; further evaluation (eg, rheumatology) may be necessary in patients developing signs and symptoms of peripheral vasculopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disorders: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bipolar disorder: May precipitate a mixed or manic episode in patients with bipolar illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Limited information exists regarding stimulant use in seizure disorder. Whereas patients with ADHD are at an increased risk for seizure activity compared to the general population, a retrospective study using drug claims data showed that the use of stimulant medications was associated with a lower risk (Cortese 2013; Wiggs 2018). Manufacturers of some stimulants recommend discontinuing therapy if seizures occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013]; Pliszka 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution in this age group due to CNS stimulant adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: <b></b>Use with caution in patients with a history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight loss: Appropriate use: Not indicated or recommended for weight loss; safety and efficacy not established for treatment of obesity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal (eg, depression, extreme fatigue).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878715"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Prior to treatment with medications for attention-deficit/hyperactivity disorder (ADHD), the American Heart Association and the American Academy of Pediatrics recommend that all children and adolescents diagnosed with ADHD have a thorough cardiovascular assessment, including patient and family health histories, determination of all medications used (prescribed and over-the-counter), and a physical examination focused on cardiovascular disease risk factors. An ECG is not mandatory but is reasonable to consider prior to stimulant medication therapy. Prompt evaluation and appropriate referral and testing, if warranted, should occur if any cardiac symptoms present (Vetter 2008).</p></div>
<div class="block foc drugH1Div" id="F24520559"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as dimesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 30 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 40 mg, 50 mg, 60 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 70 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as dimesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p></div>
<div class="block geq drugH1Div" id="F4425748"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5989464"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lisdexamfetamine Dimesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $6.60 - $14.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vyvanse Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Lisdexamfetamine Dimesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $13.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Vyvanse Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $15.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $15.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868857"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as dimesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as dimesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyvanse: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p></div>
<div class="block csi drugH1Div" id="F4425744"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block adm drugH1Div" id="F4425790"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Administer in the morning without regard to meals; avoid afternoon doses because of potential for insomnia. Do not take less than one capsule or chewable tablet per day; a single dose should not be divided.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Swallow capsule whole, do not chew. Capsule may be opened and the entire contents mixed with water, yogurt, or orange juice; stir until dispersed completely and consume the entire mixture immediately; do not store mixture. The active ingredient dissolves completely once dispersed; however, a film containing the inactive ingredients may remain in the glass or container once the mixture is consumed.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablets: Chew thoroughly before swallowing.</p></div>
<div class="block admp drugH1Div" id="F52614238"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer in the morning without regard to food; avoid afternoon doses to prevent insomnia. Do not take less than 1 chewable tablet or capsule daily; a single dose should not be divided.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Swallow capsule whole, do not chew. Capsule may be opened and the entire contents dissolved in glass of water, yogurt, or orange juice; stir until dispersed completely and consume the resulting mixture immediately; do not store the mixture. The active ingredient dissolves completely once dispersed; however, a film containing the inactive ingredients may remain in the glass or container once the mixture is consumed.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablets: Chew thoroughly before swallowing.</p></div>
<div class="block meg drugH1Div" id="F7874689"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Vyvanse: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021977s050%2C208510s007lbl.pdf%23page%3D38&amp;token=UqJnjGzXBKEfnmI9ku9catj5TaLW5cTRL2aJY%2BJQotlTI9fcCJYBWc7yFhgUfwJmoSBWvpU5DDHD%2FnhrYkeQ4jfQc7ChS6DTuW04udmFyz9yfMxXNBbqpquvMnjdQFQs&amp;TOPIC_ID=10143" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021977s050,208510s007lbl.pdf#page=38</a></p></div>
<div class="block use drugH1Div" id="F4425751"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder:</b> Treatment of moderate to severe binge eating disorder in adults.</p></div>
<div class="block mst drugH1Div" id="F4425741"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vyvanse may be confused with Glucovance, Visanne, ViVAXIM, Vytorin, Vivactil</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299610"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F4425767"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May decrease the excretion of Amphetamines. Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: May enhance the adverse/toxic effect of Amphetamines. Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a strong CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Amphetamines may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Amphetamines may enhance the analgesic effect of Opioid Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Amphetamines may enhance the cardiotoxic effect of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): Amphetamines may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Amphetamines may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Amphetamines. Tricyclic Antidepressants may potentiate the cardiovascular effects of Amphetamines. Amphetamines may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased cardiovascular effects when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F4425771"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">High-fat meal prolongs T<sub>max</sub> by ~1 hour. Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F4425753"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Lisdexamfetamine is converted to dextroamphetamine. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse 2012).</p></div>
<div class="block brc drugH1Div" id="F4425756"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Amphetamines are excreted into breast milk and use may decrease milk production. Increased irritability, agitation, and crying have been reported in nursing infants (ACOG 2011). Due to the potential for adverse reactions in a nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F4425792"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiac evaluation (including medical or family history of sudden death or ventricular arrhythmia; ECG as indicated) should be completed at baseline and on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants. Monitor blood pressure and heart rate (baseline, following dose increases and periodically during treatment); growth rate (height and weight) and appetite in children; weight in adults; signs of peripheral vasculopathy (eg, digital changes); sleep and behavioral changes; assess family history and evaluate for tics or Tourette syndrome prior to initiation of therapy; assess for new signs or worsening of tics or Tourette syndrome during treatment. Assess for risk of abuse prior to prescribing and signs of misuse, abuse, or substance use disorder throughout treatment (NICE 2018). Screen for bipolar disorder and risk factors for developing a manic episode prior to treatment; monitor for psychotic or manic symptoms (eg, delusional thinking, hallucinations, mania) or suicide-related behavior; monitor for development or worsening of aggressive behavior or hostility.</p></div>
<div class="block pha drugH1Div" id="F4425785"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The exact mechanism of lisdexamfetamine in ADHD and binge eating disorder is not known. Lisdexamfetamine dimesylate is a prodrug that is converted to the active component dextroamphetamine (a noncatecholamine, sympathomimetic amine). Amphetamines are noncatecholamine, sympathomimetic amines that cause release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.</p></div>
<div class="block phk drugH1Div" id="F4425774"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: 8 to 14 hours (Jain 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized in the blood by hydrolytic activity of red blood cells to dextroamphetamine and l-lysine; lisdexamfetamine does not undergo CYP mediated metabolism; however, dextroamphetamine is metabolized to some degree by CYP2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Lisdexamfetamine: &lt;1 hour; Dextroamphetamine: 10 to 13 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: T<sub>max</sub>: Lisdexamfetamine: Children 6 to 12 years: 1 hour (fasting); Adults: ~1 hour; Dextroamphetamine: Children 6 to 12 years: 3.5 hours (fasting); Adults: 3.8 hours (fasting), 4.7 hours (after a high-fat meal).</p>
<p style="text-indent:-2em;margin-left:4em;">Chewable tablet: T<sub>max</sub>: Lisdexamfetamine: 1 hour (fasting); Dextroamphetamine: 3.9 to 4.4 hours (fasting); 4.9 hours (after a high-fat meal).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (96%, 42% as amphetamine-related compounds, 2% as lisdexamfetamine, 25% hippuric acid); feces (minimal).</p></div>
<div class="block phksp drugH1Div" id="F51153966"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean dextroamphetamine clearance was reduced from 0.7 L/hour/kg to 0.4 L/hour/kg with severe renal impairment (GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>) and to 0.3 L/hour/kg with ESRD.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059480"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Juneve | Venvanse</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Samexid | Vyvanse</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Aduvanz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Elvanse | Elvanse adultos</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Elvanse | Elvanse Adult</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elvanse | Elvanse Adult</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tyvense</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aduvanz | Balidax | Elvanse | Volidax | Vyvanse</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Elvanse</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Elvanse | Elvanse vuxen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Vyvanse</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20141706">
<a name="20141706"></a>Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. <i>J Clin Psychiatry</i>. 2009;70(12):1652-1661. doi:10.4088/JCP.09m05335pur<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20141706/pubmed" id="20141706" target="_blank">20141706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003063">
<a name="22003063"></a>American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22003063/pubmed" id="22003063" target="_blank">22003063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343793">
<a name="21343793"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion: No. 479: Methamphetamine abuse in women of reproductive age. <i>Obstet Gynecol.</i> 2011;117(3):751-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/21343793/pubmed" id="21343793" target="_blank">21343793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577466">
<a name="17577466"></a>Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. <i>Clin Ther</i>. 2007;29(3):450-463. doi:10.1016/s0149-2918(07)80083-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/17577466/pubmed" id="17577466" target="_blank">17577466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20098534">
<a name="20098534"></a>Brahm NC, Hamilton DR. Alopecia following initiation of lisdexamfetamine in a pediatric patient. <i>Prim Care Companion J Clin Psychiatry</i>. 2009;11(6):365. doi:10.4088/PCC.08l00753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20098534/pubmed" id="20098534" target="_blank">20098534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CADDRA.1">
<a name="CADDRA.1"></a>Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. 3rd edition. Toronto, ON: CADDRA; 2011. http://caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf. Accessed July 12, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chiang.1">
<a name="Chiang.1"></a>Chiang WK. Amphetamines. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 8th edition. The McGraw-Hill Companies Inc; 2006:1119.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28667569">
<a name="28667569"></a>Coghill DR, Banaschewski T, Nagy P, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-year, open-label study in Europe. <i>CNS Drugs</i>. 2017;31(7):625-638. doi:10.1007/s40263-017-0443-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/28667569/pubmed" id="28667569" target="_blank">28667569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788672">
<a name="24788672"></a>Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. <i>CNS Drugs</i>. 2014;28(6):497-511. doi:10.1007/s40263-014-0166-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/24788672/pubmed" id="24788672" target="_blank">24788672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343808">
<a name="23343808"></a>Cooper BE, Sejnowski CA. Serotonin syndrome: recognition and treatment. <i>AACN Adv Crit Care</i>. 2013;24(1):15-22. doi:10.1097/NCI.0b013e31827eecc6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/23343808/pubmed" id="23343808" target="_blank">23343808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22043968">
<a name="22043968"></a>Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. <i>N Engl J Med</i>. 2011;365(20):1896-1904. doi:10.1056/NEJMoa1110212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22043968/pubmed" id="22043968" target="_blank">22043968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294014">
<a name="23294014"></a>Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3):227-246. doi:10.1111/jcpp.12036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/23294014/pubmed" id="23294014" target="_blank">23294014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26485338">
<a name="26485338"></a>Cressman AM, Macdonald EM, Huang A, et al. Prescription stimulant use and hospitalization for psychosis or mania: a population-based study. <i>J Clin Psychopharmacol</i>. 2015;35(6):667-671. doi:10.1097/JCP.0000000000000406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/26485338/pubmed" id="26485338" target="_blank">26485338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33675339">
<a name="33675339"></a>Davanian AM, Fitzpatrick JC, Tran DP, Korducki JP, Groth SL. Bilateral acute angle closure in a pediatric patient taking lisdexamfetamine dimesylate (Vyvanse). <i>J Glaucoma</i>. 2021;30(5):e259-e261. doi:10.1097/IJG.0000000000001826<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/33675339/pubmed" id="33675339" target="_blank">33675339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18580502">
<a name="18580502"></a>Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(9):994-1009. doi:10.1097/CHI.ObO13e31817eOea7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18580502/pubmed" id="18580502" target="_blank">18580502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20215923">
<a name="20215923"></a>Faraone SV, Spencer TJ, Kollins SH, Glatt SJ. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. <i>J Am Acad Child Adolesc Psychiatry</i>. 2010;49(1):24-32. doi:10.1097/00004583-201001000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20215923/pubmed" id="20215923" target="_blank">20215923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31133823">
<a name="31133823"></a>Ferrucci M, Limanaqi F, Ryskalin L, Biagioni F, Busceti CL, Fornai F. The effects of amphetamine and methamphetamine on the release of norepinephrine, popamine and acetylcholine from the brainstem reticular formation. <i>Front Neuroanat</i>. 2019;13:48. doi:10.3389/fnana.2019.00048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/31133823/pubmed" id="31133823" target="_blank">31133823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182674">
<a name="16182674"></a>Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. <i>J Pediatr</i>. 2005;147(3):348-354. doi:10.1016/j.jpeds.2005.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/16182674/pubmed" id="16182674" target="_blank">16182674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18622366">
<a name="18622366"></a>Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. <i>CNS Spectr</i>. 2008;13(7):614-620. doi:10.1017/s1092852900016898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18622366/pubmed" id="18622366" target="_blank">18622366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31681046">
<a name="31681046"></a>Fluyau D, Mitra P, Lorthe K. Antipsychotics for amphetamine psychosis. a systematic review. <i>Front Psychiatry</i>. 2019;10:740. doi:10.3389/fpsyt.2019.00740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/31681046/pubmed" id="31681046" target="_blank">31681046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25492713">
<a name="25492713"></a>Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/25492713/pubmed" id="25492713" target="_blank">25492713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30256542">
<a name="30256542"></a>Gnanavel S. Lisdexamfetamine and secondary Raynaud's phenomenon. <i>Prim Care Companion CNS Disord</i>. 2018;20(5):17l02240. doi:10.4088/PCC.17l02240<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/30256542/pubmed" id="30256542" target="_blank">30256542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16167346">
<a name="16167346"></a>Golub M, Costa L, Crofton K, et al. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2005;74(6):471-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/16167346/pubmed" id="16167346" target="_blank">16167346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19528194">
<a name="19528194"></a>Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. <i>Am J Psychiatry</i>. 2009;166(9):992-1001. doi:10.1176/appi.ajp.2009.09040472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/19528194/pubmed" id="19528194" target="_blank">19528194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161946">
<a name="22161946"></a>Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. <i>JAMA</i>. 2011;306(24):2673-2683. doi:10.1001/jama.2011.1830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22161946/pubmed" id="22161946" target="_blank">22161946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22559155">
<a name="22559155"></a>Hammerness P, Zusman R, Systrom D, et al. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. <i>World J Biol Psychiatry</i>. 2013;14(4):299-306. doi:10.3109/15622975.2012.678884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22559155/pubmed" id="22559155" target="_blank">22559155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20457690">
<a name="20457690"></a>Hood B, Nowicki MJ. Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. <i>Pediatrics</i>. 2010;125(6):e1510-e1513. doi:10.1542/peds.2009-1835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20457690/pubmed" id="20457690" target="_blank">20457690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26398435">
<a name="26398435"></a>Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2017;37(5):348-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/26398435/pubmed" id="26398435" target="_blank">26398435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28906602">
<a name="28906602"></a>Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord</i>. 2017;19(5):17nr02153. doi:10.4088/PCC.17nr02153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/28906602/pubmed" id="28906602" target="_blank">28906602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22430455">
<a name="22430455"></a>LaGasse LL, Derauf C, Smith LM, et al. Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age. <i>Pediatrics</i>. 2012;129(4):681-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22430455/pubmed" id="22430455" target="_blank">22430455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7580171">
<a name="7580171"></a>Lurie S, O'Quinn A. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. <i>J Neuropsychiatry Clin Neurosci</i>. 1991;3(1):41-50. doi:10.1176/jnp.3.1.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/7580171/pubmed" id="7580171" target="_blank">7580171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719291">
<a name="26719291"></a>MacKenzie LE, Abidi S, Fisher HL, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. <i>Pediatrics</i>. 2016;137(1):10.1542/peds.2015-2486. doi:10.1542/peds.2015-2486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/26719291/pubmed" id="26719291" target="_blank">26719291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29216419">
<a name="29216419"></a>Majeed MH, Ali AA, Mirza T. Frequent, spontaneous, prolonged penile erections in a 12-year-old boy after lisdexamfetamine use. <i>Prim Care Companion CNS Disord</i>. 2017;19(6):17l02139. doi:10.4088/PCC.17l02139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/29216419/pubmed" id="29216419" target="_blank">29216419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160939">
<a name="23160939"></a>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. <i>CNS Drugs</i>. 2013;27(1):15-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/23160939/pubmed" id="23160939" target="_blank">23160939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30893533">
<a name="30893533"></a>Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. <i>N Engl J Med</i>. 2019;380(12):1128-1138. doi:10.1056/NEJMoa1813751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/30893533/pubmed" id="30893533" target="_blank">30893533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE clinical guideline NG87. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87/chapter/recommendations. Published March 2018. Accessed October 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549404">
<a name="16549404"></a>Nissen SE. ADHD drugs and cardiovascular risk. <i>N Engl J Med</i>. 2006;354(14):1445-1448. doi:10.1056/NEJMp068049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/16549404/pubmed" id="16549404" target="_blank">16549404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676566">
<a name="18676566"></a>Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18676566/pubmed" id="18676566" target="_blank">18676566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S and AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26544899">
<a name="26544899"></a>Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/26544899/pubmed" id="26544899" target="_blank">26544899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31205193">
<a name="31205193"></a>Pozzi M, Carnovale C, Mazhar F, et al. Adverse drug reactions related to mood and emotion in pediatric patients treated for attention deficit/hyperactivity disorder: a comparative analysis of the US Food and Drug Administration Adverse Event Reporting System database. <i>J Clin Psychopharmacol</i>. 2019;39(4):386-392. doi:10.1097/JCP.0000000000001058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/31205193/pubmed" id="31205193" target="_blank">31205193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23382829">
<a name="23382829"></a>Schelleman H, Bilker WB, Kimmel SE, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. <i>PLoS One</i>. 2013;8(1):e52991. doi:10.1371/journal.pone.0052991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/23382829/pubmed" id="23382829" target="_blank">23382829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22318795">
<a name="22318795"></a>Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. <i>Am J Psychiatry</i>. 2012;169(2):178-185. doi:10.1176/appi.ajp.2011.11010125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22318795/pubmed" id="22318795" target="_blank">22318795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31523132">
<a name="31523132"></a>Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. <i>Int J Tryptophan Res</i>. 2019;12:1178646919873925. doi:10.1177/1178646919873925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/31523132/pubmed" id="31523132" target="_blank">31523132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27245699">
<a name="27245699"></a>Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. <i>BMJ</i>. 2016;353:i2550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/27245699/pubmed" id="27245699" target="_blank">27245699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20190905">
<a name="20190905"></a>Sichilima T, Rieder MJ. Adderall and cardiovascular risk: a therapeutic dilemma. <i>Paediatr Child Health</i>. 2009;14(3):193-195. doi:10.1093/pch/14.3.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20190905/pubmed" id="20190905" target="_blank">20190905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26998366">
<a name="26998366"></a>Sinha A, Lewis O, Kumar R, Yeruva SL, Curry BH. Amphetamine abuse related acute myocardial infarction. <i>Case Rep Cardiol</i>. 2016;2016:7967851. doi:10.1155/2016/7967851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/26998366/pubmed" id="26998366" target="_blank">26998366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20693523">
<a name="20693523"></a>Silva RR, Skimming JW, Muniz R. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. <i>Clin Pediatr (Phila)</i>. 2010;49(9):840-851. doi:10.1177/0009922810368289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/20693523/pubmed" id="20693523" target="_blank">20693523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9685453">
<a name="9685453"></a>Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. <i>Pediatrics</i>. 1998;102(2, pt 3):501-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/9685453/pubmed" id="9685453" target="_blank">9685453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32792083">
<a name="32792083"></a>Torres-Acosta N, O'Keefe JH, O'Keefe CL, Lavie CJ. Cardiovascular effects of ADHD therapies: JACC review topic of the week. <i>J Am Coll Cardiol</i>. 2020;76(7):858-866. doi:10.1016/j.jacc.2020.05.081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/32792083/pubmed" id="32792083" target="_blank">32792083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423. doi:10.1161/CIRCULATIONAHA.107.189473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25653508">
<a name="25653508"></a>Vo K, Neafsey PJ, Lin CA. Concurrent use of amphetamine stimulants and antidepressants by undergraduate students. <i>Patient Prefer Adherence</i>. 2015;9:161-172. doi:10.2147/PPA.S74602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/25653508/pubmed" id="25653508" target="_blank">25653508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vyvanse.1">
<a name="Vyvanse.1"></a>Vyvanse (lisdexamfetamine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vyvanse.2">
<a name="Vyvanse.2"></a>Vyvanse (lisdexamfetamine) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Westfall.1">
<a name="Westfall.1"></a>Westfall TC, Westfall DP. Adrenergic Agonists and Antagonists. In: Brunton LL, ed. <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i>. 11th ed. McGraw-Hill; 2006:257-258.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22682429">
<a name="22682429"></a>Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. <i>BMC Cardiovasc Disord</i>. 2012;12:41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22682429/pubmed" id="22682429" target="_blank">22682429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476037">
<a name="29476037"></a>Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. <i>Neurology</i>. 2018;90(13):e1104-e1110. doi:10.1212/WNL.0000000000005213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/29476037/pubmed" id="29476037" target="_blank">29476037</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10143 Version 319.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
